JP2025506389A - ｐ－タウ１８１レベルを使用した治療方法 - Google Patents

ｐ－タウ１８１レベルを使用した治療方法 Download PDF

Info

Publication number
JP2025506389A
JP2025506389A JP2024545951A JP2024545951A JP2025506389A JP 2025506389 A JP2025506389 A JP 2025506389A JP 2024545951 A JP2024545951 A JP 2024545951A JP 2024545951 A JP2024545951 A JP 2024545951A JP 2025506389 A JP2025506389 A JP 2025506389A
Authority
JP
Japan
Prior art keywords
subject
months
dose
tau
protofibril antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506389A5 (https=
Inventor
彰比古 小山
マイケル イリザリー，
道雄 兼清
リン クレイマー，
ジューン カプロウ，
デイビッド バーベル，
ショバ ダッダ，
パラヴィ サチデブ，
ラリサ レイダーマン，
誠一 早戸
イシャニ ランドリー，
ロバート ゴードン，
チャド スワンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2025506389A publication Critical patent/JP2025506389A/ja
Publication of JP2025506389A5 publication Critical patent/JP2025506389A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2024545951A 2022-02-02 2022-11-09 ｐ－タウ１８１レベルを使用した治療方法 Pending JP2025506389A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263306060P 2022-02-02 2022-02-02
US63/306,060 2022-02-02
US202263269394P 2022-03-15 2022-03-15
US63/269,394 2022-03-15
US202263364617P 2022-05-12 2022-05-12
US63/364,617 2022-05-12
PCT/US2022/079571 WO2023149970A1 (en) 2022-02-02 2022-11-09 Methods of treatment using p-tau181 level

Publications (2)

Publication Number Publication Date
JP2025506389A true JP2025506389A (ja) 2025-03-11
JP2025506389A5 JP2025506389A5 (https=) 2025-11-18

Family

ID=84488881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545951A Pending JP2025506389A (ja) 2022-02-02 2022-11-09 ｐ－タウ１８１レベルを使用した治療方法

Country Status (11)

Country Link
US (1) US20250377367A1 (https=)
EP (1) EP4473009A1 (https=)
JP (1) JP2025506389A (https=)
KR (1) KR20240142535A (https=)
AU (1) AU2022439338A1 (https=)
CA (1) CA3243435A1 (https=)
CL (1) CL2024002309A1 (https=)
IL (1) IL314581A (https=)
MX (1) MX2024009492A (https=)
TW (1) TW202339794A (https=)
WO (1) WO2023149970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025260029A1 (en) * 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
KR20220084095A (ko) * 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
RS67249B1 (sr) 2020-03-20 2025-10-31 Eisai R&D Man Co Ltd Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe

Also Published As

Publication number Publication date
CL2024002309A1 (es) 2025-01-24
KR20240142535A (ko) 2024-09-30
TW202339794A (zh) 2023-10-16
CA3243435A1 (en) 2023-08-10
US20250377367A1 (en) 2025-12-11
AU2022439338A1 (en) 2024-08-15
MX2024009492A (es) 2024-08-09
WO2023149970A1 (en) 2023-08-10
IL314581A (en) 2024-09-01
EP4473009A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
JP7541505B2 (ja) アルツハイマー病の治療及び予防方法
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2017537905A (ja) アルツハイマー病の治療法
JP2019517540A (ja) アルツハイマー病を治療する方法
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
JP2025539394A (ja) タウｐｅｔレベルを使用する治療の方法
JP2024532438A (ja) 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN118786141A (zh) 使用p-tau181水平的治疗方法
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2026015877A1 (en) Fluid biomarker
KR20260038283A (ko) 항미생물 펩티드

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20241029

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110